Professionals 224 Users Online

COVID-19 Saliva-based Screening Market

Improvement of COVID-19 Testing and International Funding will drive the Global Market for COVID-19 Saliva-based Screening over the Forecast Duration

COVID-19 Saliva-based Screening Market Segmented By Saliva Collection Kits, Saliva Nucleic Acid Purification Kits, Saliva-based Detection Kits Product with Direct Sample to PCR, RT-qPCR, Lateral Flow Assays Technology

COVID-19 Saliva-based Screening Market Outlook (2023-2033)

Worldwide revenue from the COVID-19 saliva-based screening market stands at US$ 2.1 Bn in 2022, with the global market estimated to decline at a CAGR of -1.5% to reach US$ 1.6 Bn by the end of 2033.

Attributes Key Insights

COVID-19 Saliva-based Screening Market Size (2022)

US$ 2.1 Bn

Projected Market Value (2033)

US$ 1.6 Bn

Global Market Growth Rate (2023-2033)

-1.5% CAGR

Market Share of Top 5 Countries

60.5%

As assessed by Persistence Market Research, saliva-based detection kits contributed the largest share of 82.8% in the product category in 2022. The COVID-19 saliva-based screening market holds approximately 1% of the global health screening market valued at US$ 241.1 Bn in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of COVID-19 Saliva-based Screening Market from 2020 to 2022 Vs Market Outlook for 2023 to 2033

The global market for COVID-19 saliva-based screening market recorded a historic CAGR of 9.9% in the last 2 years from 2020 to 2022.

The overall market for COVID-19 saliva-based screening products is likely to decline over time due to a growing focus on vaccination throughout regions, support from developing countries that can offer vaccinations to non-developed regions, and the population developing vaccination.

The disease has had a very high incidence rate ever since the COVID-19 pandemic in 2019. It had an impact on almost all nations in the world. The number of cases worldwide increased exponentially after COVID-19 was identified.

Developing nations like India saw similar effects as industrialised ones like the United States and Europe experienced. The virus's high level of inter-person transmission was a crucial factor in its fast expansion. Worldwide demand for COVID-19 diagnostics increased as a result of this, demanding companies to enter into this space with increased R&D and subsequently COVID-19 diagnostic kits and vaccines development.

  • For instance, in April 2021, Chembio Diagnostics, Inc. announced the launch of a U.S. FDA-approved rapid POCT for COVID-19/Flu A&B test.
  • The US Food and Drug Administration has authorised a first saliva test for the detection of severe acute respiratory syndrome coronavirus 2 infections as of April 15, 2020.
  • A study found that in 2020, there were 23,487 death cases reported among the 25 million males over 65 in the U.S., compared to 2,765 fatality cases reported among the 31 million women over 65. The new COVID-19 saliva test is believed to make testing simpler for people of any age because the saliva-based procedure permits a quicker and easier collection of samples.
  • In 2020, the Africa Centres for Disease Control and Prevention aimed to increase testing for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from 1300 per million to 16 000 per million populations. They surpassed their goal; by early 2022, over 95 million tests had been performed (about 74 000 tests per million people).

Demand for COVID-19 testing has increased as a result of the COVID-19 pandemic. In addition, there have been instances of the second wave in a few countries over the past two quarters, and the second and third waves are expected to spread to additional nations and the market is likely to show steady growth over the coming years.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How are COVID-19 Saliva-based Screening Manufacturers Growing?

“Improvement of COVID-19 Testing and International Funding”

Saliva-based techniques can help testing programmes in low- and middle-income nations become more affordable, scalable, and sustainable. Saliva is more sensitive than anterior nasal and mid-turbinate swabs in early infection detection, and it is equally as effective at detecting SARS-CoV-2.

This observation has held true in the wake of the emergence and global dissemination of the Omicron strain of SARS-CoV-2. Saliva testing aids lower- and middle-income nations in overcoming two major issues: a lack of resources and overworked medical workers.

Comparatively speaking, saliva-based testing methods are less expensive. Saliva samples do not need pricey, specialised collection tubes because they are stable without preservatives and cold-chain management. Additionally, saliva-based testing does not call for highly skilled medical personnel, specific swab supplies, or personal safety gear.

When compared to nasopharyngeal swabs, a meta-analysis calculated that saliva collection saves up to US$ 633,000 for every 100,000 patients sampled. Additionally, patients can self-collect saliva at clinics and testing facilities, lessening their discomfort.

Additionally, because there are fewer healthcare employees per capita in lower- and middle-income nations than in high-income ones, the strategy lowers the danger of occupational exposure to infection for healthcare professionals.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

How is Market Progress Being Affected to Some Extent?

“Nasal Swab- Competition for Market Players”

Other specimens, like blood and nasopharyngeal swabs for detection, are what drive the industry today. Due to the ease with which saliva may be used for both self-detection and clinical purposes, its use is increasing substantially.

Despite this, a lot of new businesses are releasing testing kits that use nasal swabs, which is limiting the market growth.

One of the biggest constraints as human health behaviours is the completion of global vaccination. COVID-19 testing has been reduced due to immunisation consolidation.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. COVID-19 Saliva-based Screening Market Booming?

“Government Funding Programs for COVID-19”

The U.S. accounted for a 31.7% share of the global market in 2022, and a similar trend is expected over the forecast period.

The World Health Organization (WHO) reported over 96.8 million confirmed cases of COVID-19 in the United States as of November 11, 2022. In terms of revenue and profitability, United States currently leads the COVID-19 saliva screening market and will continue to do so during the forecast period. Of the 50 states that have been affected, California, Texas, and Florida have reported the most instances overall.

This is because of the presence of key competitors in the country, high healthcare costs, and growing use of novel technologies in hospitals.

  • According to the Global fund together with FIND and other ACT-Accelerator partners, the Global Fund, the United States, and Unite are providing over US$120 million in assistance to countries for test-and-treat programmes to protect those in low- and middle-income countries who are most at risk from COVID-19 hospitalizations and deaths.
  • The World Health Organization (WHO) reports that between January 17 and January 23, 2022, the number of new COVID-19 cases increased globally by 5%.

Why is China Emerging as a Prominent Market for COVID-19 Saliva-based Screening Suppliers?

“Rising Requirement of COVID-19 Saliva-based Testing”

China held the largest market share of 89.1% of the East Asia COVID-19 saliva-based screening market in 2022, with a market value of US$ 151.5 Mn.

According to the Journal of the Chinese Medical Association in one study, 205 oropharyngeal and 490 nasopharyngeal swabs from 213 hospitalised SARS-CoV-2 patients were analysed at various stages of the disease's progression. Regardless of whether the patients had mild or severe disease, they discovered that nasopharyngeal swabs had generally higher positive rates (53.6%-73.3%) than oropharyngeal (throat) swabs (11.1%-61.3%).

Despite immunisation campaigns, most people in China have not yet received the vaccine, and the vaccine is ineffective against mutant versions. As a result, the first appearance of a new variant in China opens up a variety of options for established local players.

Will India be a Lucrative Market for COVID-19 Saliva-Based Screening?

“High Prevalence of COVID-19 and Increasing Saliva-Based Screening”

In 2022, India held around 75.7% share of the South Asian market.

To meet patient demand for diagnosis and treatment in the event of such a pandemic, India faces enormous challenges. The second wave of COVID-19 patients overloaded diagnostic facilities, leading to increased cross-infection and COVID-19 spread. With the aid of saliva-based detection kits, this can be reduced.

Self-detection kits are becoming more popular as a way for people to obtain test results with less danger of cross-infection. Future market developments in India may benefit from this.

  • Additionally, according to the Indian council of medical Research (ICSR), India completed 909.9 million tests by December 4, 2022.
  • One of India's diagnostics equipment manufacturers, Angstrom Biotech Pvt. Ltd., successfully launched "Angcard," India's first COVID-19 saliva-based household testing kit, on December 21, 2021.

Category-wise Insights

Which Technology is driving the Global Market Growth?

“Rising Incidence of COVID-19”

The technology sector is anticipated to have the highest demand for RT-qPCR testing, and it is anticipated to continue to account for a significant portion of revenue, almost 48.9%, as it did in 2022.

An effective screening method for cruise ships, airlines, sporting venues, and colleges is COVID-19 saliva screening antigen/antibodies testing, which enables quick identification of those who are currently contagious. The COVID-19 saliva-screening test for antigens and antibodies has the potential to significantly reduce the risks of the pandemic.

Moreover, a larger population over the age of 65 is likely to be at risk of developing the condition, as evidenced by the rising number of the mentioned age group. As a result, the demand for COVID-19 saliva-based screening is anticipated to increase as the population ages and becomes more vulnerable to viral infections.

Which COVID-19 Saliva-based Detection Product is Driving Market Growth?

“Home-Based Testing for SARS-COVID-19 Infection will Drive Market”

In 2022, saliva based detection kits dominated the product category with 82.8% of the COVID-19 saliva-based detection market. Over the decade, saliva-based detection as a specimen is predicted to fuel market expansion due to rising awareness of home-based testing for SARS-COVID-19 infection.

Over the projected period, PCR-based kits will dominate the market. Due to the growing use of COVID-19 saliva-based detection kits, there is a high demand for these products.

PCR-based kits for the identification of the SARS-CoV-2 coronavirus provide high sensitivity and specificity. Due to widespread knowledge of COVID-19 detection, self- testing is also rising.

Why Market Share for COVID-19 Diagnostics is high in the Application Segment?

“Growing Awareness of COVID-19 Detection”

In 2022, the COVID-19 diagnostics category held the highest share with over 62.7%.

After 2-3 months from release from lockdowns, more COVID-19 cases were seen as a result of people failing to maintain social distancing in public settings. As a result, many nations made the diagnosis of COVID-19 mandatory.

In order to interrupt the cycle, people also learned more about COVID-19 treatment methods and testing. Even those with weak flu or cough symptoms underwent detection tests.

As a result, there is a higher need for COVID-19 testing. To meet demand, RT-PCR is the most effective way to use saliva to quickly and accurately detect COVID-19 infection.

Why are Diagnostic Laboratories in Such High Demand?

“Growing Awareness of COVID-19 Detection”

In 2022, diagnostic laboratories held 26.9% share of the global market, which is the highest among the end users segment.

In order to detect pathogen-specific nucleic acids in samples, qPCR uses sequence-specific primers and probes to monitor the amplification of the nucleic acid molecules during PCR. The SARS-CoV-2 viral genome's relative stability facilitates the construction of PCR primers and probes for laboratory identification.

Due to the rising COVID-19 prevalence and increased virus mutation, which has boosted the demand for quicker and more accurate detection, diagnostic laboratories will present lucrative market growth opportunities. Laboratories have been crucial in verifying the diagnosis of COVID-19 and identifying affected people, but this segment has also faced significant challenges in the fight against this rapidly spreading and fatal disease.

Competitive Landscape

Several leading players are focusing on advancements in in-vitro diagnostic procedures with rapid testing and expanding their product portfolios through the commercialization of products and product launches to increase their customer base and expand their sales footprint across the globe.

For instance,

  • In March 2020, Abbott launched ID NOW, a molecular POCT for detecting novel coronavirus (COVID-19), authorized by the U.S. FDA-issued Emergency Use Authorization (EUA). It is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and uses molecular technology that delivers positive results in under five minutes and negative results in 13 min.
  • Chembio Diagnostics, Inc. introduced an FDA Emergency Use Authorized POCT for COVID-19 in April 2021. This test is used in both standard and decentralized diagnostic labs.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the COVID-19 saliva-based screening market, which are available in the full report.

COVID-19 Saliva-based Screening Market Report Scope

Attribute Details

Forecast Period

2023-2033

Historical Data Available for

2020-2022

Market Analysis

  • USD Million for Value
  • Units for Volume

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Technology
  • Application
  • End User
  • Region

Key Companies Profiled

  • Thermo Fisher Scientific
  • Qiagen
  • Hologic
  • Takara Bio Inc
  • Arcis Biotechnology Limited
  • GeneProof
  • Abacus ALS
  • Chai Inc.
  • Kolplast Group
  • Lucence Health Inc
  • Vitagene
  • Therma Bright Inc
  • ACON Laboratories, Inc
  • TODA PHARMA
  • Norgen Biotek Corp.
  • Assure Tech. (Hangzhou) Co., Ltd
  • Nantong Diagnos Biotechnology Co., Ltd
  • NeuMoDx Molecular, Inc.
  • KYODO INTERNATIONAL INC.
  • Canvax
  • Zymo Research Corporation.
  • Salimetrics
  • NEST Scientific USA
  • Mawi DNA Technologies

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments of the COVID-19 Saliva-based Screening Industry Research

Product:

  • Saliva Collection Kits
  • Saliva Nucleic Acid Purification Kits
  • Saliva-based Detection Kits
    • Rapid Test Kits
    • PCR-based Kits

Technology:

  • Direct Sample to PCR
  • RT-qPCR
  • Lateral Flow Assays

Application:

  • COVID-19 Research
  • COVID-19 Diagnostics

End User:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic and Research Institutes
  • Biopharma Companies
  • Long Term Care Facilities
  • Home Care Settings
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Thermo Fisher Scientific
  • Qiagen
  • Hologic
  • Takara Bio Inc
  • Arcis Biotechnology Limited
  • GeneProof
  • Abacus ALS
  • Chai Inc.
  • Kolplast Group
  • Lucence Health INc
  • Vitagene
  • Therma Bright Inc
  • ACON Laboratories, Inc
  • TODA PHARMA
  • Norgen Biotek Corp.
  • Assure Tech. (Hangzhou) Co., Ltd
  • Beijing Hotgen Biotech Co., Ltd
  • Nantong Diagnos Biotechnology Co., Ltd
  • NeuMoDx Molecular, Inc.
  • KYODO INTERNATIONAL INC.
  • Canvax
  • Zymo Research Corporation.
  • Salimetrics
  • NEST Scientific USA
  • Miraclean Technology Co. Ltd
  • Mawi DNA Technologies
  • Cell Projects Ltd.

- Frequently Asked Questions -

The global market for COVID-19 saliva-based screening is valued at around US$ 2.1 Bn in 2022.

By 2033, the market for COVID-19 saliva-based screening is anticipated to decline at a CAGR of -1.5% and reach US$ 1.6 Bn.

Demand for COVID-19 saliva-based screening increased at 9.9% CAGR from 2020 to 2022.

With a combined market share of 60.5% in 2022, the U.S., Russia, India, China, and U.K. accounted for the majority of demand for the COVID-19 saliva based screening market.

The U.S. accounted for a 31.7% share of the global market in 2022.

Thermo Fisher Scientific, Qiagen, and Hologic are the top three manufacturers of the COVID-19 Saliva-based Screening kits.

China held a share of 89.1% in the East Asian market in 2022.

The Russia COVID-19 saliva-based screening market is valued at US$ 157.4 Mn in 2022.

Indian market in estimated to grow with the growth rate of -3.6% over the forecast period.

European market is expected to decline at a CAGR of -1.3% during the forecast period.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate